|
1
|
Bhatt JR and Finelli A: Landmarks in the
diagnosis and treatment of renal cell carcinoma. Nat Rev Urol.
11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shuch B, Amin A, Armstrong AJ, Eble JN,
Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI and Kutikov A:
Understanding pathologic variants of renal cell carcinoma:
Distilling therapeutic opportunities from biologic complexity. Eur
Urol. 67:85–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Escudier B, Porta C, Schmidinger M, Algaba
F, Patard JJ, Khoo V, Eisen T and Horwich A; ESMO Guidelines
Working Group, : Renal cell carcinoma: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25
Suppl 3:iii49–iii56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abe H and Kamai T: Recent advances in the
treatment of metastatic renal cell carcinoma. Int J Urol.
20:944–955. 2013.PubMed/NCBI
|
|
5
|
Rahman M and Hasan MR: Cancer metabolism
and drug resistance. Metabolites. 5:571–600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Linehan WM, Srinivasan R and Schmidt LS:
The genetic basis of kidney cancer: A metabolic disease. Nat Rev
Urol. 7:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shayman JA: Targeting glycosphingolipid
metabolism to treat kidney disease. Nephron. 134:37–42. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Czarnecka AM, Niedzwiedzka M, Porta C and
Szczylik C: Hormone signaling pathways as treatment targets in
renal cell cancer (Review). Int J Oncol. 48:2221–2235. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mondul AM, Weinstein SJ, Moy KA, Männistö
S and Albanes D: Vitamin D-binding protein, circulating vitamin D
and risk of renal cell carcinoma. Int J Cancer. 134:2699–2706.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thiele I, Swainston N, Fleming RM, Hoppe
A, Sahoo S, Aurich MK, Haraldsdottir H, Mo ML, Rolfsson O, Stobbe
MD, et al: A community-driven global reconstruction of human
metabolism. Nat Biotechnol. 31:419–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer genome atlas research, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wittekind C: 2010 TNM system: On the 7th
edition of TNM classification of malignant tumors. Pathologe.
31:331–332. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kolde R: Pheatmap: Pretty Heatmaps. R
package version 1.0.8. 2015, https://CRAN.R-project.org/package=pheatmap
|
|
14
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expressionanalyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang Z, Hu S, Hua D, Ni J, Xu L, Ge Y,
Zhou Y, Cheng Z and Wu S: β3GnT8 plays an important role in CD147
signal transduction as an upstream modulator of MMP production in
tumor cells. Oncol Rep. 32:1156–1162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen L, Yu M, Xu X, Gao L, Ni J, Luo Z and
Wu S: Knockdown of β3GnT8 reverses 5-fluorouracil resistance in
human colorectal cancer cells via inhibition the biosynthesis of
polylactosamine-type N-glycans. Int J Oncol. 45:2560–2568. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Shen L, Yang L, Hu S, Xu L and Wu
S: High expression of β3GnT8 is associated with the metastatic
potential of human glioma. Int J Mol Med. 33:1459–1468. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hua D, Qin F, Shen L, Jiang Z, Zou ST, Xu
L, Cheng ZH and Wu SL: β3GnT8 regulates laryngeal carcinoma cell
proliferation via targeting MMPs/TIMPs and TGF-β1. Asian Pac J
Cancer Prev. 13:2087–2093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lien HC, Lee YH, Jeng YM, Lin CH, Lu YS
and Yao YT: Differential expression of hyaluronan synthase 2 in
breast carcinoma and its biological significance. Histopathology.
65:328–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Warrington NM, Sun T and Rubin JB:
Targeting brain tumor cAMP: The case for sex-specific therapeutics.
Front Pharmacol. 6:1532015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong H, Claffey KP, Brocke S and Epstein
PM: Expression of phosphodiesterase 6 (PDE6) in human breast cancer
cells. SpringerPlus. 2:6802013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Law V, Knox C, Djoumbou Y, Jewison T, Guo
AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, et al:
DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids
Res. 42:D1091–D1097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong Y, Kim WJ, Bang CY, Lee JC and Oh YM:
Identification of alternative splicing and fusion transcripts in
non-small cell lung cancer by RNA sequencing. Tuberc Respir Dis
(Seoul). 79:85–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nicastri A, Gaspari M, Sacco R, Elia L,
Gabriele C, Romano R, Rizzuto A and Cuda G: N-glycoprotein analysis
discovers new up-regulated glycoproteins in colorectal cancer
tissue. J Proteome Res. 13:4932–4941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nisman B, Appelbaum L, Yutkin V,
Nechushtan H, Hubert A, Uziely B, Pode D and Peretz T: Serum
thymidine kinase 1 activity following nephrectomy for renal cell
carcinoma and radiofrequency ablation of metastases to lung and
liver. Anticancer Res. 36:1791–1797. 2016.PubMed/NCBI
|
|
26
|
Wenners A, Hartmann F, Jochens A, Roemer
AM, Alkatout I, Klapper W, van Mackelenbergh M, Mundhenke C, Jonat
W and Bauer M: Stromal markers AKR1C1 and AKR1C2 are prognostic
factors in primary human breast cancer. Int J Clin Oncol.
21:548–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang L, Seino J, Tomotake H, Funakoshi Y,
Hirayama H and Suzuki T: Co-Expression of NEU2 and GBA3 causes a
drastic reduction in cytosolic sialyl free N-glycans in human MKN45
stomach cancer cells-evidence for the physical interaction of NEU2
and GBA3. Biomolecules. 5:1499–1514. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gilkes DM, Bajpai S, Wong CC, Chaturvedi
P, Hubbi ME, Wirtz D and Semenza GL: Procollagen lysyl hydroxylase
2 is essential for hypoxia-induced breast cancer metastasis. Mol
Cancer Res. 11:456–466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Edqvist PH, Huvila J, Forsström B, Talve
L, Carpén O, Salvesen HB, Krakstad C, Grénman S, Johannesson H,
Ljungqvist O, et al: Loss of ASRGL1 expression is an independent
biomarker for disease-specific survival in endometrioid endometrial
carcinoma. Gynecol Oncol. 137:529–537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu G, Hou G, Li L, Li Y, Zhou W and Liu
L: Potential diagnostic and prognostic marker dimethylglycine
dehydrogenase (DMGDH) suppresses hepatocellular carcinoma
metastasis in vitro and in vivo. Oncotarget. 7:32607–32616. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu Z, Yao Y, Song Q, Yang J, Zhao X, Yang
P and Kang J: Metabolism-related enzyme alterations identified by
proteomic analysis in human renal cell carcinoma. Onco Targets
Ther. 9:1327–1337. 2016.PubMed/NCBI
|
|
32
|
Joh HK, Giovannucci EL, Bertrand KA, Lim S
and Cho E: Predicted plasma 25-hydroxyvitamin D and risk of renal
cell cancer. J Natl Cancer Inst. 105:726–732. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shang Y, Yi S, Cui D, Han G and Liu C:
Vitamin E Intake and risk of renal cell carcinoma: A meta-analysis
of 7 case-control studies. J Ren Nutr. 25:339–344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mitsui Y, Chang I, Fukuhara S, Hiraki M,
Arichi N, Yasumoto H, Hirata H, Yamamura S, Shahryari V, Deng G, et
al: CYP1B1 promotes tumorigenesis via altered expression of CDC20
and DAPK1 genes in renal cell carcinoma. BMC Cancer. 15:9422015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Narjoz C, Favre A, McMullen J, Kiehl P,
Montemurro M, Figg WD, Beaune P, de Waziers I and Rochat B:
Important role of CYP2J2 in protein kinase inhibitor degradation: A
possible role in intratumor drug disposition and resistance. PLoS
One. 9:e955322014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Trachootham D, Alexandre J and Huang P:
Targeting cancer cells by ROS-mediated mechanisms: A radical
therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rodrigues D, Monteiro M, Jeronimo C,
Henrique R, Belo L, Bastos ML, de Pinho P Guedes and Carvalho M:
Renal cell carcinoma: A critical analysis of metabolomic biomarkers
emerging from current model systems. Transl Res. 180:1–11. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Masui K, Cavenee WK and Mischel PS: Cancer
metabolism as a central driving force of glioma pathogenesis. Brain
Tumor Pathol. 33:161–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Johnson C, Warmoes MO, Shen X and Locasale
JW: Epigenetics and cancer metabolism. Cancer Lett. 356:309–314.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Monteiro MS, Carvalho M, de Lourdes Bastos
M and de Pinho PG: Biomarkers in renal cell carcinoma: A
metabolomics approach. Metabolomics. 10:1210–1222. 2014. View Article : Google Scholar
|
|
41
|
Kim K, Taylor SL, Ganti S, Guo L, Osier MV
and Weiss RH: Urine metabolomic analysis identifies potential
biomarkers and pathogenic pathways in kidney cancer. OMICS.
15:293–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shim EH, Livi CB, Rakheja D, Tan J, Benson
D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, et al:
L-2-Hydroxyglutarate: An epigenetic modifier and putative
oncometabolite in renal cancer. Cancer discov. 4:1290–1298. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Armitage EG and Barbas C: Metabolomics in
cancer biomarker discovery: Current trends and future perspectives.
J Pharm Biomed Anal. 87:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
You L, Zhang B and Tang YJ: Application of
stable isotope-assisted metabolomics for cell metabolism studies.
Metabolites. 4:142–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hakimi AA, Reznik E, Lee CH, Creighton CJ,
Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, et al: An
integrated metabolic atlas of clear cell renal cell carcinoma.
Cancer Cell. 29:104–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schwanhausser B, Busse D, Li N, Dittmar G,
Schuchhardt J, Wolf J, Chen W and Selbach M: Global quantification
of mammalian gene expression control. Nature. 473:337–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nagaraj N, Wisniewski JR, Geiger T, Cox J,
Kircher M, Kelso J, Pääbo S and Mann M: Deep proteome and
transcriptome mapping of a human cancer cell line. Mol Syst Biol.
7:5482011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Meng FD, Ma P, Sui CG, Tian X and Jiang
YH: Association between cytochrome P450 1A1 (CYP1A1) gene
polymorphisms and the risk of renal cell carcinoma: A
meta-analysis. Sci Rep. 5:81082015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chang I, Fukuhara S, Wong DK, Gill A,
Mitsui Y, Majid S, Saini S, Yamamura S, Chiyomaru T, Hirata H, et
al: Cytochrome P450 1B1 polymorphisms and risk of renal cell
carcinoma in men. Tumour Biol. 35:10223–10230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Quivy A, Daste A, Harbaoui A, Duc S,
Bernhard JC, Gross-Goupil M and Ravaud A: Optimal management of
renal cell carcinoma in the elderly: A review. Clin Interv Aging.
8:433–442. 2013.PubMed/NCBI
|
|
51
|
Wang G, Hou J, Ma L, Xie J, Yin J, Xu D,
Chang W, Tan X, Su T, Zhang H and Cao G: Risk factor for clear cell
renal cell carcinoma in Chinese population: A case-control study.
Cancer epidemiol. 36:177–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sverko A, Sobočanec S, Kusic B, Kušić B,
Mačak-Šafranko Z, Sarić A, Leniček T, Kraus O, Andrišić L, Korolija
M, et al: Superoxide dismutase and cytochrome P450 isoenzymes might
be associated with higher risk of renal cell carcinoma in male
patients. Int Immunopharmacol. 11:639–645. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kollmannsberger C, Soulieres D, Wong R,
Scalera A, Gaspo R and Bjarnason G: Sunitinib therapy for
metastatic renal cell carcinoma: Recommendations for management of
side effects. Can Urol Assoc J. 1 Suppl 2:S41–S54. 2007.PubMed/NCBI
|
|
54
|
McFadyen MC, Melvin WT and Murray GI:
Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J
Cancer. 91:966–971. 2004. View Article : Google Scholar : PubMed/NCBI
|
